| Hypertensive disease

Benicar HCT vs CaroSpir

Side-by-side clinical, coverage, and cost comparison for hypertensive disease.

Deep comparison between: Benicar Hct vs Carospir with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsCarospir has a higher rate of injection site reactions vs Benicar Hct based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Carospir but not Benicar Hct, including UnitedHealthcare

Category

Benicar Hct

Carospir

At A Glance

RouteOral

FrequencyDaily

ClassARB / thiazide diuretic

RouteOral

FrequencyDaily

ClassAldosterone antagonist

Indications

Hypertensive disease

Heart failure with reduced ejection fraction
Hypertensive disease
Edema

Dosing

Hypertensive disease Starting dose 40/12.5 mg or 20/12.5 mg once daily depending on prior monotherapy; titrate up to 40/25 mg if needed.

Heart failure with reduced ejection fraction Initiate at 20 mg once daily; may increase to 37.5 mg once daily as clinically indicated; may reduce to 20 mg every other day if hyperkalemia develops; consider initiating at 10 mg once daily in patients with eGFR 30-50 mL/min/1.73m2.

Hypertensive disease Initiate at 20 to 75 mg daily in single or divided doses; titrate at two-week intervals; doses >75 mg/day generally do not provide additional blood pressure reduction.

Edema Initiate in a hospital setting at 75 mg daily in single or divided doses; titrate slowly; administer for at least five days before increasing dose to obtain desired effect.

Contraindications

Hypersensitivity to any component of BENICAR HCT
Anuria
Coadministration with aliskiren in patients with diabetes

Hyperkalemia
Addison's disease
Concomitant use of eplerenone

Drug Interactions

2334View drug interactions

1197View drug interactions

Adverse Reactions

Most common (>2%) Dizziness, upper respiratory infection, hyperuricemia, nausea

Serious Hypotension, impaired renal function, hypersensitivity reactions, electrolyte and metabolic imbalances, acute myopia and secondary angle-closure glaucoma, systemic lupus erythematosus, sprue-like enteropathy

Postmarketing Asthenia, vomiting, hyperkalemia, rhabdomyolysis, alopecia, pruritus

Serious Hyperkalemia, hypotension, worsening renal function, electrolyte and metabolic abnormalities, gynecomastia, impaired neurological function or coma in patients with hepatic impairment and cirrhosis with ascites

Postmarketing Gastric bleeding, ulceration, gastritis, nausea, vomiting, diarrhea, gynecomastia, decreased libido, erectile dysfunction, irregular menses, amenorrhea, postmenopausal bleeding, leukopenia, agranulocytosis, thrombocytopenia, fever, urticaria, anaphylactic reactions, vasculitis, hyponatremia, hypovolemia, leg cramps, lethargy, mental confusion, ataxia, dizziness, headache, renal dysfunction, renal failure, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, alopecia, pruritus, chloasma, cholestatic/hepatocellular toxicity

Pharmacology

Olmesartan medoxomil selectively blocks angiotensin II binding to the AT1 receptor in vascular smooth muscle, inhibiting vasoconstriction independent of angiotensin II synthesis pathways; hydrochlorothiazide is a thiazide diuretic that directly increases renal excretion of sodium and chloride, reducing plasma volume to lower blood pressure.

Aldosterone antagonist; spironolactone and its active metabolites competitively bind aldosterone receptors at the sodium-potassium exchange site in the distal convoluted renal tubule, increasing sodium and water excretion while retaining potassium, exerting diuretic and antihypertensive effects.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Benicar Hct